Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual’s stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI’s facilities are located in Madison, Wisconsin. See http://www.cellulardynamics.com.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. They operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals Inc., Medimmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com.
PsychoGenics is a Preclinical CRO with expertise in the CNS and orphan disorders. Known for cutting edge translational approach to research, customized solutions, as well as identifying statistically relevant phenotypic changes, even early and subtle changes, that help clients quantify the efficacy of their treatments before they move into the clinic.
MRM Proteomics Inc. is a leader in providing advanced mass spectrometry based quantitative proteomics services and reagents to the pharmaceutical, biotechnology and diagnostics industries in key areas such as biomarker discovery/validation and clinical diagnostics development. For additional information, please go to http://www.mrmproteomics.com.
About PROOF Centre: The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) develops blood tests to diagnose, treat and manage heart, lung and kidney disease. The PROOF Centre is a cross-disciplinary engine of partners representing academia, health care, government, industry, patients and the public, to improve heart, lung and kidney health and reduce the enormous socioeconomic burden of organ disease. The centre’s service arm provides expertise in computation, “-omic” science and biomarker workflow to organizations seeking to discover, develop and implement blood-based molecular biomarkers in a clinical setting. The PROOF Centre is a not-for-profit society initially established from the Networks of Centres of Excellence Secretariat under the Centre of Excellence for Commercialization and Research (NCE CECR) Program, and is co-hosted by the University of British Columbia and Providence Health Care in Vancouver, British Columbia, Canada. For additional information, please go to http://www.proofcentre.ca.
Dr. Bartoli is a CNRS researcher and the Co-Head of Translational Myology team at the Faculty of Medicine Timone Aix Marseille Université, INSERM UMR_S910 research unit (Marseille, France). Dr. Krahn is an Associate-Professor in Prof. Nicolas Lévy's labs: Laboratory of Molecular Genetics in the Department of Medical Genetics at the Children's Hospital La Timone; and the Co-Head of Translational Myology team at the Faculty of Medicine Aix Marseille Université, INSERM UMR_S910 research unit (Marseille, France).
Nenad Bursac is a Professor of Biomedical Engineering, Cell Biology, and Medicine, and director of Cardiac Electrophysiology and Tissue Engineering Laboratory at Duke University. He is one of the pioneers and leaders of the cardiac and skeletal muscle tissue engineering fields. Currently, Dr. Bursac’s research efforts are focused on engineering of stem cell-based striated muscle tissues, in vitro modeling of muscle physiology and disease, and cell- and gene-based therapies for heart and skeletal muscle disorders. Recently, Dr. Bursac’s group has been the first to develop functional models of human skeletal muscle from primary and induced pluripotent stem cells.
Dr. Chakravorty is a principal investigator in the Department of Pediatrics and Human Genetics at Emory University (Atlanta, GA).
Dr. Staub is the Harold Macmillan Professor of Medicine at the John Walton Muscular Dystrophy Research Centre in the Institute of Human Genetics at Newcastle University.
Noah Lucas Weisleder, PhD is a professor in the Department of Physiology and Cell Biology at Ohio State University Wexner Medical Center.